Experimental Study On The Mechanisms Of Anti-Bronchial Asthma Oral Liquid Rats Model With Asthma

Objective:The study was established on the basis of bronchial asthma rat model, while giving the anti-bronchial asthma oral liquid intervention, we explore that rat model mechanism in the anti-bronchial asthma oral liquid heal cough variant asthma about immunohistochemistry, pathology aspects and Cell Biology through animal experiments, the results of this study for which anti-bronchial asthma oral liquid healed bronchial asthma in children to provide experimental evidence.Method:1. Animal groups and the establishment of animal modelWe will the of70wistar adult rats that its weight120to150g, these rats by the Experimental Animal Center of Heilongjiang University of Chinese Medicine.After3days, We refer to the relevant literature, the researchers used the rats in each group, except for the normal group, the rest of the rats in experiments1and8days, intraperitoneal injection of10%ovalbumin, aluminum hydroxide mixture of1ml of a total of2ml, Injection in rats on both sides of the waist, in order to make the sensitization. Since the fifteenth day, the researchers applied3%ovalbumin40ml spray excited in models of asthma, the atomization flow control in5ml per minute, for15minutes each time, once every two days, consecutive four weeks in order to stimulate. The the rat appears rapid breathing, lips cyanosis, nodded breathing and standing instability and other symptoms, these symptoms indicate that inspire success.The50sucessful rats after3days were randomly divided into control group, model group, dexamethasone group, anti-support oral high, medium and low dose group. We will the other10wistar adult rats as normal group, Group of normal saline instead of ovalbumin by intraperitoneal injection and inhalation.2. Experimental animals gavage and drawnResearchers begin to the first provocation (the modeling3weeks) to each treatment group before being killed daily irrigation0.5h gastric administration before the atomization high dose group40mg/kg/d, middle dose group20mg/kg/d, low dose group10mg/kg/d, western medicine (dexamethasone) group, giving0.5mg/kg/d dexamethasone orally; sustained delivery of four weeks, the normal group with normal saline.The experimental animals were weighed before modeling; Thereafter rats were weighed every5days, the rats were drawn before the last weighing; excited after4weeks, the rats on experimental rats per unit time within the respiratory frequencyand the number of sneezing records.2hours after the last administration, the experimental animals were anesthetized, and then drawn. Researcher take each rat lung tissue, bronchoalveolar lavage fluid (BALF) and serum to spare. Associated enzyme-linked immunosorbent assay (ELISA) method for the determination of lung tissue LTB4, LTC4content and associated reverse transcriptase method for the determination of serum IL-5mRNA expression, and IgE levels in serum were measured by radio immunoassay.3. The experimental results(1) Lung histopathological changes.The study found that the lung tissue of the model under a microscope to generate a large number of inflammatory cell infiltration, airway mucosal edema associated with shedding of epithelial cells, subepithelial fibrosis, smooth muscle thickening. Chinese medicine, the low-dose group lung tissue of rats with the model group, these changes significantly reduced, compared with the dexamethasone group, there was no significant difference.(2) Each index changeThe experimental results show that anti-bronchial asthma oral liquid1can significantly reduce a major regulator of inflammatory factors IL-5mRNA levels in asthmatic rats serum, then reduce airway inflammation District EOS proliferation, differentiation, aggregation and activation, to achieve the purpose of the control of airway inflammation; It can also reduce the generation of suffering from asthma rat serum immunoglobulin E (IgE), to reduce the differentiation of mast cells and slow down the growth of eosinophil chemotaxis and activation, reduce asthma eosinophilic airway inflammation. It can reduce the serum of asthma-induced airway inflammation-mediated airway epithelial cell damage off the strong alkaline granule protein ECP content; and reduce inflammatory mediators in the lung tissue LTB4, LTC4; and reduce asthma BALFeosinophils in bronchoalveolar lavage fluid (BALF) supernatant anti-bronchial asthma oral liquid through a multi-level, multi-channel, multi-target control airway inflammation of asthma rat model, it can reduce the high reactivity of the airways of asthmatic rats, so it has broad application prospects.Conclusion:1. Each dose group of anti-bronchial asthma oral liquid can improve the general symptoms, reduce inflammatory infiltration, submucosal edema, reduce the production of secretions in asthmatic rats, thereby reducing airway narrowing and airway hyperresponsiveness, especially high dose group and medium dose group.2. High dose group and medium dose group of anti-bronchial asthma oral liquid can reduce the content of eosinophils and lymphocytes in lung tissue, which indicated that anti-bronchial asthma oral liquid can control airway inflammation by reducing eosinophils and lymphocytes content in the lung tissue.3. anti-bronchial asthma oral liquid can significantly reduce the expression of IL-5mRNA in the lung tissue of asthmatic rats, reduce the infiltration of inflammatory cells, thereby to reduce airway inflammation and relieve airway spasm state.4. ECP content in the peripheral blood of asthmatic rats had been significantly reduced by high dose group and medium dose group, thereby inhibited the activation of EOS, to protect the respiratory epithelium, reduce AHR, inhibit allergic reactions, eventually to achieve the effect of resolving phlegm to relieve cough, anti-inflammatory and relieving allergy. 5. anti-bronchial asthma oral liquid can significantly reduce IgE levels in the peripheral blood of asthmatic rats, and reduce the incidence of type I allergic reaction of asthma, so as to achieve the purpose of controlling asthma attacks.6. High dose group and medium dose group of anti-bronchial asthma oral liquid can reduce the content of LTB4and LTC4in lung tissue, which indicated that anti-bronchial asthma oral liquid can reduce asthma airway inflammation and slow down the bronchial smooth muscle contraction to relieve asthma symptoms by reducing LTB4and LTC4.